Technology | Computer-Aided Detection Software | November 30, 2018

Infervision’s deep learning medical imaging platform acts as second pair of eyes to identify multiple diseases from one set of chest scans

Infervision Introduces AI Capabilities for Chest CT Reading

November 30, 2018 — Big data and artificial intelligence (AI) company Infervision announced the launch of InferRead CT Chest, a new product concept that detects four different conditions with just one set of chest scans, leading to faster and more comprehensive medical diagnoses. Additionally, Infervision introduced a new product concept for fast diagnosis in emergency conditions. The announcements were made at the 2018 Radiological Society of North America (RSNA) conference, Nov. 25-30 in Chicago.

The new InferRead CT (computed tomography) Chest will allow a doctor to review an image only once to perform multiple disease screenings in the chest including:

  • Lung nodule screening;

  • Chest fractures, bone metastases and bone tumor screenings;

  • Chronic lung disease (such as emphysema) screening; and

  • Cardiac calcification screening.

The lung nodule screening, while a core Infervision product, has been enhanced over the past year so it can now provide a complete view of the nodule, including volume and density. This product can automatically compare similar cases from a case report bank to provide further information and diagnostic information to physicians.

Also introduced by Infervision at RSNA is a new product concept which aims to help manage emergency conditions including stroke and bone fractures. The product allows doctors to use AI for fast diagnosis and treatment decisions. With this concept, the company is using the power of AI to improve emergency room workflow, and it is now being tested and continually improved in several hospitals in China.

Used to reduce the highly-repetitive work radiologists do each day, the goal of Infervision is to help doctors deliver more accurate reports faster. In fact, when Infervision’s technology and a group of radiologists recently went head-to-head in a report-reading experiment with different types and sizes of nodules. Infervision’s AI-CT predicted more accurately than radiologists in every category.

For more information: www.infervision.com


Related Content

News | HIMSS

March 5, 2026 — At the Health Information and Management Systems Society (HIMSS) Conference & Exhibition 2026 in Las ...

Time March 06, 2026
arrow
News | Radiation Oncology

March 4, 2026 — Lunit has announced that 21 studies featuring its AI solutions will be presented at the European ...

Time March 05, 2026
arrow
News | Artificial Intelligence

March 2, 2026 — RadNet, Inc. has acquired Gleamer SAS, a radiology AI company based in Paris, France. Gleamer will be ...

Time March 03, 2026
arrow
News | Ultrasound Women's Health

March 2, 2026 — Ultrasound AI, a provider of artificial intelligence applications for medical imaging, has received FDA ...

Time March 03, 2026
arrow
News | Ultrasound Imaging

March 2, 2026 — Esaote Group will officially launch the new MyLab E85 and MyLab C30 GTS Edition ultrasound systems at ...

Time March 02, 2026
arrow
News | Remote Viewing Systems

Feb. 26, 2026 — DeepHealth, Inc., a provider of AI-powered health informatics and a wholly owned subsidiary of RadNet ...

Time February 27, 2026
arrow
News | FDA

Feb. 26, 2026 — The U.S. Food and Drug Administration (FDA) has given 510(k) class II clearance of qXR-Detect, the ...

Time February 26, 2026
arrow
News | Ultrasound Imaging

Feb. 25, 2026 — GE HealthCare is introducing the next generation of LOGIQ general imaging ultrasound systems – an ...

Time February 25, 2026
arrow
News | Women's Health

Feb.23, 2026 — The first clinical patient received a Clairity Breast cancer risk score, marking a historic milestone in ...

Time February 23, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

Feb. 19, 2026 — GE HealthCare recently announced 510(k) clearance of three new magnetic resonance (MR) innovations with ...

Time February 20, 2026
arrow
Subscribe Now